Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

Iván O. Rosas(Brigham and Women's Hospital), Min Bao(California Institute of Technology), Steffen Wildum(Roche (Switzerland)), Lorenzo Del Sorbo(University Health Network), Nichola Cooper(Imperial College London), Lothar Wiese(Zealand University Hospital), Sanjay Bhagani, Daniel J. Skiest(Baystate Medical Center), Rebecca N. Bauer, Nidhi Rohatgi(The University of Texas MD Anderson Cancer Center), Ronaldo C. Go, Cor H. van der Leest(Roche (Canada)), Ivan T. Lee, Atul Malhotra(Monash Health), Louis M. Metcalf(Roche (United Kingdom)), Jordi Carratalà(Instituto de Salud Carlos III), David J. De La Zerda(University of Miami), Balpreet Matharu(Roche (United Kingdom)), Kevin G. Blyth(Queen Elizabeth University Hospital), Antonio Cubillo Gracián(Hospital Universitario HM Sanchinarro), Bradley D. Hunter(Intermountain Healthcare), Emily Graham(Roche (United Kingdom)), Norbert Bräu(James J. Peters VA Medical Center), Julia Garcia‐Diaz(Ochsner Medical Center), Paolo Bonfanti(University of California San Diego), Ivor S. Douglas(Westchester Medical Center), Thomas Benfield(University of Copenhagen), Michael R. Waters(Washington University in St. Louis), Mariam Aziz(Rush University Medical Center), Taryn Youngstein(Imperial College London), Larry Tsai, Derrick S. Haslem(Intermountain St. George Regional Hospital), Bruno François(Inserm), Charles Edouard Luyt(Sorbonne Université), Sinisa Savic(University of Leeds), Fang Cai, Andrew Ustianowski(North Manchester General Hospital)
EClinicalMedicine
April 21, 2022
Cited by 37


Related Papers